These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. Lorentzen T; Skjoldbye BO; Nolsoe CP Ultraschall Med; 2011 Oct; 32(5):492-6. PubMed ID: 21259183 [TBL] [Abstract][Full Text] [Related]
25. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075 [TBL] [Abstract][Full Text] [Related]
26. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT. Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549 [TBL] [Abstract][Full Text] [Related]
28. A Novel CT to Cone-Beam CT Registration Method Enables Immediate Real-Time Intraprocedural Three-Dimensional Assessment of Ablative Treatments of Liver Malignancies. Solbiati M; Passera KM; Goldberg SN; Rotilio A; Ierace T; Pedicini V; Poretti D; Solbiati L Cardiovasc Intervent Radiol; 2018 Jul; 41(7):1049-1057. PubMed ID: 29492634 [TBL] [Abstract][Full Text] [Related]
29. The impact of 18F-FDG PET/CT in patients with liver metastases. Chua SC; Groves AM; Kayani I; Menezes L; Gacinovic S; Du Y; Bomanji JB; Ell PJ Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766 [TBL] [Abstract][Full Text] [Related]
30. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy. Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573 [TBL] [Abstract][Full Text] [Related]
31. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma? van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861 [TBL] [Abstract][Full Text] [Related]
32. Percutaneous radiofrequency ablation of malignant liver tumors with ultrasound and CT fusion imaging guidance. Xu ZF; Xie XY; Kuang M; Liu GJ; Chen LD; Zheng YL; Lu MD J Clin Ultrasound; 2014; 42(6):321-30. PubMed ID: 24615771 [TBL] [Abstract][Full Text] [Related]
33. A Comparative Study of SonoVue and Sonazoid for Contrast-Enhanced Ultrasound CT/MRI Fusion Guidance During Radiofrequency Ablation of Poorly Visualized Hepatic Malignancies: A Prospective Intra-Individual Analysis. Kim H; Kim JH; Lee JM Ultrasound Med Biol; 2024 Dec; 50(12):1879-1884. PubMed ID: 39306481 [TBL] [Abstract][Full Text] [Related]
34. Assessment of liver ablation using cone beam computed tomography. Abdel-Rehim M; Ronot M; Sibert A; Vilgrain V World J Gastroenterol; 2015 Jan; 21(2):517-24. PubMed ID: 25593467 [TBL] [Abstract][Full Text] [Related]
35. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET. García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715 [TBL] [Abstract][Full Text] [Related]
36. The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases. Nielsen K; Scheffer HJ; Pieters IC; van Tilborg AA; van Waesberghe JH; Oprea-Lager DE; Meijerink MR; Kazemier G; Hoekstra OS; Schreurs HW; Sietses C; Meijer S; Comans EF; van den Tol PM BMC Med Imaging; 2014 Aug; 14():27. PubMed ID: 25103913 [TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced ultrasonography-CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome. Lee Y; Yoon JH; Han S; Joo I; Lee JM Cancer Imaging; 2024 Jan; 24(1):4. PubMed ID: 38172949 [TBL] [Abstract][Full Text] [Related]
38. The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. Nanni C; Zompatori M; Ambrosini V; Montesi V; Mezzetti S; Ferretti A; Chondrogiannis S; Rubello D; Fanti S Biomed Pharmacother; 2013 Mar; 67(2):172-8. PubMed ID: 23433901 [TBL] [Abstract][Full Text] [Related]
39. Ultrasound and cone beam CT fusion for liver ablation: technical note. Monfardini L; Orsi F; Caserta R; Sallemi C; Della Vigna P; Bonomo G; Varano G; Solbiati L; Mauri G Int J Hyperthermia; 2018; 35(1):500-504. PubMed ID: 30204007 [TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases. D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]